Prospective, Observational, Multicentre Study Evaluating HCV Patients Characteristics of Eligibility and Disease Management in Real Clinical Practice.

Trial Profile

Prospective, Observational, Multicentre Study Evaluating HCV Patients Characteristics of Eligibility and Disease Management in Real Clinical Practice.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Nov 2012

At a glance

  • Drugs Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Schering-Plough
  • Most Recent Events

    • 08 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Sep 2011 Planned end date changed from 1 Aug 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
    • 09 Dec 2010 Planned End Date changed from 1 Jun 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top